Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 58% Improvement Relative Risk Ventilation 65% Hospitalization 69% Cough score, day 7 29% Cough score, day 3 10% Samajdar et al. Budesonide for COVID-19 LATE Is late treatment with budesonide+formoterol beneficial for COVID-19? Prospective study of 102 patients in India (January - June 2021) Improved recovery with budesonide+formoterol (p=0.0082) Samajdar et al., Lung India, doi:10.4103/lungindia.lungindia_268_22 Favors budesonide Favors control
Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study
Samajdar et al., Lung India, doi:10.4103/lungindia.lungindia_268_22
Samajdar et al., Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19.., Lung India, doi:10.4103/lungindia.lungindia_268_22
Mar 2023   Source   PDF  
  All Studies   Meta
Prospective study of 102 patients in India, showing improved recovery of cough with budesonide+formoterol. Authors note better results with earlier treatment. Budesonide 800mcg + formoterol 12mcg bid for 7 days.
risk of death, 58.4% lower, RR 0.42, p = 0.44, treatment 2 of 50 (4.0%), control 5 of 52 (9.6%), NNT 18.
risk of mechanical ventilation, 65.3% lower, RR 0.35, p = 0.62, treatment 1 of 50 (2.0%), control 3 of 52 (5.8%), NNT 27.
risk of hospitalization, 68.8% lower, RR 0.31, p = 0.07, treatment 3 of 50 (6.0%), control 10 of 52 (19.2%), NNT 7.6.
cough score, 29.4% lower, RR 0.71, p = 0.008, treatment mean 2.14 (±1.24) n=50, control mean 3.03 (±1.99) n=52, day 7.
cough score, 9.9% lower, RR 0.90, p = 0.10, treatment mean 4.66 (±1.42) n=50, control mean 5.17 (±1.65) n=52, day 3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Samajdar et al., 3 Mar 2023, prospective, India, peer-reviewed, mean age 47.2, 6 authors, study period January 2021 - June 2021, this trial uses multiple treatments in the treatment arm (combined with formoterol) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBudesonideAll
Abstract: Original Article CX1AWnYQp/IlQrHD3i3D0OdRyi7TvSFl4Cf3VC1y0abggQZXdtwnfKZBYtws= on 03/07/2023 Effectiveness of budesonide formoterol fixed‑dose combination MDI in reducing cough symptoms in COVID‑19 patients: A real‑world evidence study Shambo Samrat Samajdar1, Shatavisa Mukherjee2, Saibal Moitra3, Jyotirmoy Pal4, Shashank Joshi5, Santanu Kumar Tripathi6 Consultant at Diabetes and Allergy-Asthma Specialty Clinic, Kolkata & Clinical Pharmacologist at School of Tropical Medicine, Kolkata, West Bengal, India, 2Department of Clinical and Experimental Pharmacology, School of Tropical Medicine, Kolkata, West Bengal, India, 3 Department of Respiratory Medicine, Division of Allergy and Immunology, Apollo Multispeciality Hospital, Kolkata, West Bengal, India, 4Department of Medicine, R G Kar Medical College and Hospital, Kolkata, West Bengal, India, 5Department of Diabetology and Endocrinology, Joshi Clinic, Lilavati Hospital and Research Centre, Mumbai, Maharashtra, India, 6Department of Pharmacology, Netaji Subhas Medical College and Hospital, Patna, Bihar, India 1 ABSTRACT Background: Cough is a wearisome and exasperating symptom affecting the daily life of the infected patient. Cough due to coronavirus disease 2019 (COVID‑19) causes excessive morbidity in human populations globally. Apart from the morbidity associated with cough, it also enhances the transmission of this viral infection through droplets. Therefore, curbing cough is crucial to limit its spread. Patients often administer over‑the‑counter products and antitussive agents, which have no proven benefit. The present study was undertaken to find out if cough associated with COVID‑19 and other indicative clinical outcomes is alleviated with a budesonide/formoterol fixed‑dose combination (FDC) metered‑dose inhaler (MDI). Materials and Methods: A prospective observational study was conducted in mild COVID‑19 patients who presented with a cough score ≥8 at presentation. Patients who were initiated on ICS-LABA MDI were observed as group A and those who were not initiated on MDI were observed as Group B. Cough symptom score (at baseline and on day 3 and day 7), the incidence of hospital admission and/or death, and need for mechanical ventilation were documented. Prescribing patterns of anti‑cough medications were also noted and analysed. Results: Compared to group B, a higher mean cough score reduction was noted for group A patients at day 3 and day 7 when compared to the baseline, and this was significant at P < 0.001. A significant negative correlation was also observed between mean latency of MDI initiation from the symptom onset and mean cough score reduction. Analysis of the proportion of patients prescribed medications to treat cough showed that overall, 10.78% did not require these, with a greater proportion in group A compared to group B. Conclusion: Patients infected with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) COVID‑19 who were treated with ICS-LABA MDI along with usual care benefitted significantly in terms of symptom reduction compared to usual care. KEY WORDS: Budesonide formoterol fixed‑dose combination MDI, cough symptoms, COVID‑19 Address for correspondence: Dr. Shambo Samrat Samajdar, Consultant at Diabetes and Allergy-Asthma Specialty Clinic, Kolkata and Clinical Pharmacologist at School of Tropical Medicine, Kolkata, West Bengal, India. E‑mail:..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop